ChanRx touts Phase IIb vanoxerine data ahead of fundraising, partnership
This article was originally published in Scrip
Executive Summary
Phase IIb data for ChanRx's vanoxerine show that the oral drug may offer safety benefits versus other therapies for the treatment of atrial fibrillation, which could bolster the Cleveland, Ohio-based company's prospects for raising venture capital or attracting a partner to finance a Phase III clinical trial.